Disease in a Dish: Creating Human Tissues In Vitro

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Drug Delivery

Intracellular Delivery: Reaching Targets Beyond the Cell Surface

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Next-Gen Delivery

Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms

Pharma's Almanac

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

LAIs

The Long View: How Extended-Duration Therapies Are Reshaping Patient Care

Pharma's Almanac

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

CRO Partnerships

Building Resilient Development Models: How Mid-Size Pharma Can Scale Without Losing Control

Brian Healey

IQVIA